Thromb Haemost 1996; 75(03): 510-514
DOI: 10.1055/s-0038-1650306
Original Article
Schattauer GmbH Stuttgart

A Prostacyclin-sparing Effect of Indobufen vs. Aspirin

R De Caterina
The CNR Institue of Clinical Physiology, Pisa, Italy
,
D Giannessi
The CNR Institue of Clinical Physiology, Pisa, Italy
,
W Bernini
The CNR Institue of Clinical Physiology, Pisa, Italy
,
G Lazzerini
The CNR Institue of Clinical Physiology, Pisa, Italy
,
M Lavezzari
1   Pharmacia-Farmitalia Carlo Erba, Milan, Italy
,
E Stragliotto
1   Pharmacia-Farmitalia Carlo Erba, Milan, Italy
,
G Biagi
2   Chair and Department of Angiology and Blood Coagulation, University of Bologna, Italy
,
S Coccheri
2   Chair and Department of Angiology and Blood Coagulation, University of Bologna, Italy
› Author Affiliations
Further Information

Publication History

Received 21 August 1995

Accepted after revision 21 November 1995

Publication Date:
26 July 2018 (online)

Summary

Indobufen ((±)-2-[p-(l-oxo-2-insoindolinyl)-phenyI]-butyric acid, indo) is a drug inhibiting platelet function by a reversible block of the arachidonic acid metabolism at the level of cyclooxygenase. Since tolerability profile of such drugs is mostly linked to extra-platelet cyclooxygenase inhibition, we prospectively evaluated the extent of platelet and extra-platelet cyclooxygenase inhibition by in vivo administration of indo in comparison with ASA. We assessed the effects of the two drugs on the ex vivo generation of TXB2 and 6-keto-PGF in whole blood, as indices of the production of TXA2 and PGI2 (prostacyclin), respectively, either after spontaneous clotting at 37° C for 1 h (Study 1) or after the addition of 2 Μg/ml collagen (Study 2). Generation of 6-keto-PGF in whole blood is a mixed index of platelet and extra-platelet cyclooxygenase activity, deriving from both platelet and white blood cell arachidonic acid metabolization. Fifteen patients with ischemic heart disease and baseline serum TXB2 levels > 300 ng/ml were allocated to receiving one single administration of either indobufen 200 mg (n = 6) or aspirin 500 mg (n = 9). Whole blood prostanoid generation was assessed at 0,1,2,4,6, 8,12 and 24 h after drug administration (Study 1). Ten healthy male volunteers were allocated to a double-blind, randomized crossover comparison of indo 200 mg b.i.d. vs. ASA 300 mg/d for 7 days (Study 2). Prostanoid generation and whole blood platelet aggregation were performed before and at the end of each study period (Day 0 and Day 7). At each time-point after single dose administration (Study 1), indobufen caused less % inhibition of whole blood 6-keto-PGF than of TXB2. At 2 h, TXB2 was reduced to a similar extent after ASA (98 ± 4%) and indo (97 ± 6%) (p = N.S.), while inhibition of 6-keto-PGFla was clearly different (> 98% after ASA, 81 ± 2.5% after indo, p < 0.01). After one week of ASA or indo (Study 2) the maximum extent of whole blood platelet aggregation was similarly inhibited (from 17.2 ± 1.4 ohms to 3.6 ± 1.3 ohms with ASA; from 18.3 ± 1.0 ohms to 1.6 ± 0.7 ohms with indo (p ASA vs. indo = N. S.). Despite equal inhibition of whole blood TX production after collagen (from 49.0 ± 4.3 ng/ml to 1.1 ± 0.6 ng/ml with ASA, from 49.8 ± 1.3 ng/ml to 1.4 ± 0.6 ng/ml with indo), again, however, 6-keto-PGF production was less affected by indo than by ASA (from 409 ± 30 pg/ml to 37 ± 13 pg/ml with ASA, inhibition = 91%; from 396 ± 35 to 318 ± 40 with indo, inhibition = 20%). These differential effects of indo and ASA might lead to a better platelet selectivity, tolerability and benefit/risk profile of indo vs. ASA, which are worthy of further assessment.

 
  • References

  • 1 Vinazzer H, Fuccella L. Clinical pharmacology studies with indobufen (K3920), inhibitor of platelet aggregation. J Clin Pharmacol 1980; 20: 316-325
  • 2 Mannucci L, Madema P, Colli S, Lavezzari M, Sirtori C, Tremoli E. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res 1987; 48: 417-426
  • 3 Patrignani P, Volpi D, Ferrario R, Romanzini L. Effect of racemic, S- and R-indobufen on cyclooxygenase and lipooxygenase activities in human whole blood. Eur J Pharmacol 1990; 191: 83-88
  • 4 De Caterina R, Sicari R, Yan A, Bernini W, Giannessi D, Lazzerini G, Ef-thymiopoulos C, Strolin-Benedetti M. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. Thromb Haemost 1992; 67: 258-263
  • 5 Cattaneo M, Bevilacqua C, Lecchi A, Mannucci P. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production. Haemostasis 1987; 17: 293-300
  • 6 Pinto S, Abbate R, Favilla S, Paneta A, Gensini G, Neri Serneri G. Ex vivo and in vitro study of the effects of indobufen on endogenous and exogenous arachidonic acid metabolism by platelets. Curr Ther Res 1987; 42: 243-252
  • 7 Salter M, Mayor P, Crow M, Rajah S, Davison A. Microthrombus formation on hemodialysis membranes: A placebo-controlled randomized trial of two doses of indobufen. Clin Nephrol 1985; 24: 31-36
  • 8 Italian Multicenter Study Group. Long-term antiplatelet activity and safety of indobufen on patients with cardiovascular disease. Int J Pharmacol Toxicol 1985 23. 439-446
  • 9 Signorini G, Salmistraro G, Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology 1988; 39: 742-746
  • 10 Di Minno G, Silver M. Mouse antithrombotic assay: A simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983 225. 57-60
  • 11 Peters S, Jonker J, Boer A, Den Ottolander G. The incidence of deep venous thrombosis in patients with an acute myocardial infarction treated with acenocoumarol or indobufen. Thromb Haemost 1982; 4: 222-225
  • 12 Fomaro G, Rossi P, Mantica P, Caccia M, Aralda D, Lavezzari M, Milanen G. Indobufen in the prevention of thromboembolic complications in patients with cardiac disease. A pilot study. Eur Heart J 1990 11. 168 P850 (Abstract).
  • 13 Fornaro G, Rossi P, Mantica P, Caccia M, Aralda D, Lavezzari M, Pamparana F, Milanesi G. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation 1993; 87: 162-164
  • 14 Flower RJ, Moncada S. R VJ, Analgesic-antipyretics and antiinflammatory agents. In Goodman-Gilman A, Goodman S, Gilman A. (Eds.) The Pharmacological Basis of Therapeutics. New York: Mac Millan Publishing Co: 1980: 682-728
  • 15 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980; 3: 135-158
  • 16 Giannessi D, De Caterina R, Gazzetti P, Bernini W, Masini S, Zucchelli GC. Methodological assessment and applications of a radioimmunoassay for thromboxane (TX) B2 release by platelets. J Nucl Med All Sci 1982; 26: 25-33
  • 17 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2 . Thromb Res 1982; 26: 389-400
  • 18 Giannessi D, Lazzerini G, Sicari R, De Caterina R. Vasoactive eicosanoids in the rat heart: clues to a contributory role of cardiac thromboxane to post-ischaemic hyperaemia. Pharmacol Res 1992; 26: 341-356
  • 19 Roth CJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particular fraction protein. J Clin Invest 1975; 56: 624-632
  • 20 Cerbone AM, Salvia F, Farinaro E, Ferrara LA, Quarto G, De Franciscis S. et al. Differential inhibition by indobufen (K3920) of platelets and vascular prostaglandin synthesis in man. Proceedings VIII International Congress on Thrombosis - Istanbul (Turkey), June 4-7 1984 (Abstract).
  • 21 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
  • 22 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
  • 23 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
  • 24 De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell’Amico F, L’Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985; 54: 528-532
  • 25 Pawlowski MA, Kaplan G, Hamill AL, Cohen ZA, Scott WA. Arachidonic acid metabolism by human monocytes. J Exp Med 1983; 158: 393-412
  • 26 Maclouf J, Fitzpatrick F, Murphy R. Transcellular biosynthesis of eicosan-oids. Pharmacol Res 1989; 21: 1-5
  • 27 Marcus AJ. Eicosanoid interactions between platelets, endothelial cells, and neutrophils. Methods Enzymol 1990; 187: 585-599
  • 28 Marcus AJ. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism. Blood 1990; 76: 1903-1907
  • 29 Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C. Differential effects of dazoxiben, a selective thromboxane synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. J Pharmacol Exp Ther 1984; 228: 472-477
  • 30 De Caterina R, Sicari R, Giannessi D, Paggiaro PL, Paoletti P, Lazzerini G, Bernini W, Solid E, Parente L. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. J Appl Physiol 1993; 75: 2368-2375
  • 31 Davì G, Francavilla G, Mattina A, Catalano I, Licata G, Strano A. Indo-bufen treatment in angina pectoris: effects on platelet function and thromboxane synthesis. Curr Ther Res 1988; 43: 1031-1037
  • 32 Latif AB, Mason C, Sheehan SJ, Rajah SM, Kester RC. Influence of aspirin and indobufen on recovery of platelet and vessel wall eicosanoid production and blood loss in patients undergoing coronary artery bypass surgery. Thromb Haemost 1989; 62: 245
  • 33 The SINBA Group (Studio Indobufene nel Bypass Aortocoronarico). Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coronary Artery Disease 1991; 2: 897-906